To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

306

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

February 21, 2023

Study Completion Date

June 30, 2023

Conditions

Healthy

Interventions

BIOLOGICAL

ADL-018

150 mg/mL, Solution for injection in PFS

BIOLOGICAL

US-licensed XOLAIR

150 mg/mL, Solution for injection in PFS

BIOLOGICAL

EU-Approved XOLAIR

150 mg/mL, Solution for injection in PFS

Trial Locations (2)

Registered BABE centre, Ahmedabad

Registered BABE Centre, Mahesāna